form10qsb.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
_______________________
FORM
10-QSB
(Mark
One)
[ X ] QUARTERLY
REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For
Quarterly period Ended: September 30, 2005; or
[
] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE
ACT OF 1934
For
the transition period __________ to __________
Commission
File Number: 0-21271
_________________________
SANGUI
BIOTECH INTERNATIONAL, INC.
________________________________________________
(Exact
name of Small Business Issuer as specified in its charter)
COLORADO
84-1330732
______________________
___________
(State
or
other Jurisdiction
of (I.R.S.
Employer
Incorporation
or
Organization) Identification
No.)
Alfred-Herrhausen-Str.
44, 58455 Witten, Germany
_____________________________
(Address
of principal executive offices)
011-49-2302-915-204
___________________________________
(Issuer's
telephone number, including area code)
Check
whether
the issuer: (1) filed all reports required to be filed by Section 13 or 15(d)
of
the Exchange Act during the past12 months (or for such shorter period that
a
registrant was required to file such reports), and (2) has been subject to
such
filing requirements for the past 90 days. Yes o No
x
Indicate
by
check mark whether the registrant is a shell company (as defined in Rule 12b-2
of the Exchange Act). Yes o No
x
The
number of
shares outstanding of the issuer's common stock, no par value, as of August
25,
2007, was 50,000,000
Transitional
Small Business Disclosure Format. Yes o No
x
SANGUI
BIOTECH INTERNATIONAL, INC.
Report
on
Form 10-QSB
For
the
Quarter Ended September 30, 2005
INDEX
----------
Page
Part
I. Financial Information
Item
1. Consolidated Financial Statements
.........................................................
2
Consolidated
Balance Sheets
..........................................................................
2
Consolidated
Statements of Operations and Comprehensive Loss
..........
4
Consolidated
Statements of Cash Flows
.......................................................
5
Notes
to the Consolidated Financial Statements
......................................... 6
Item
2. Management's Discussion and Analysis or Plan of Operation
.........
12
Item
3. Controls and Procedures
.......................................................................... 14
Part
II.
Other Information
Item
1. Legal Proceedings
.....................................................................................
14
Item
2. Unregistered Sales of Equity Securities and Use of Proceeds
...........
14
Item
3. Defaults Upon Senior Securities
..............................................................
14
Item
4. Submission of Matters to a Vote of Security Holders
..........................
14
Item
5. Other Information
......................................................................................
14
Item
6. Exhibits
.........................................................................................................
14
ii
PART
I -
FINANCIAL INFORMATION
Item
1 –
Consolidated Financial Statements
_________________________________
The
accompanying unaudited consolidated financial statements have been prepared
in
accordance with the instructions to Form 10-QSB pursuant to the rules and
regulations of the Securities and Exchange Commission and, therefore, do not
include all information and footnotes necessary for a complete presentation
of
our financial position, results of operations, cash flows, and stockholders'
deficit in conformity with generally accepted accounting principles in the
United States of America. In the opinion of management, all adjustments
considered necessary for a fair presentation of the consolidated results of
operations and financial position have been included and all such adjustments
are of a normal recurring nature.
Our
unaudited
consolidated balance sheet as of September 30, 2005 and our unaudited
consolidated statements of operations for the three month periods ended
September 30, 2005 and 2004, and the unaudited consolidated statements of cash
flows for the three month periods ended September 30, 2005 and 2004, are
attached hereto and incorporated herein by this reference.
1
|
|
Consolidated
Balance Sheets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September
30,
|
|
|
June
30,
|
|
|
|
|
|
2005
|
|
|
2005
|
|
CURRENT
ASSETS
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
|
|
|
|
$ |
12,231
|
|
|
$ |
9,497
|
|
Accounts
receivable
|
|
|
3,842
|
|
|
|
4,300
|
|
Inventory
|
|
|
|
7,048
|
|
|
|
7,063
|
|
Prepaid
expenses and other assets
|
|
|
13,467
|
|
|
|
17,421
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Current Assets |
|
|
36,588
|
|
|
|
38,281
|
|
|
|
|
|
|
|
|
|
|
|
|
FIXED
ASSETS, Net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property
and
equipment
|
|
|
22,774
|
|
|
|
33,608
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Fixed Assets |
|
|
22,774
|
|
|
|
33,608
|
|
|
|
|
|
|
|
|
|
|
|
|
OTHER
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Patents
and licenses, net
|
|
|
0
|
|
|
|
2,490
|
|
Other
miscellaneous assets
|
|
|
45,842
|
|
|
|
90,814
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Other Assets |
|
|
45,842
|
|
|
|
93,304
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL
ASSETS |
|
$ |
105,204
|
|
|
$ |
165,193
|
|
The
accompanying condensed notes are an integral part of these interim consolidated
financial statements.
2
|
|
Consolidated
Balance Sheets (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS' EQUITY (DEFICIT)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September
30,
|
|
|
June
30,
|
|
|
|
|
|
2005
|
|
|
2005
|
|
|
|
|
|
(Unaudited)
|
|
|
|
|
CURRENT
LIABILITIES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts
payable and accrued expenses
|
|
$ |
159,170
|
|
|
$ |
140,899
|
|
Notes
payable
|
|
|
|
-
|
|
|
|
24,132
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Current Liabilities
|
|
|
159,170
|
|
|
|
165,031
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL
LIABILITIES, COMMITMENTS AND CONTINGENCIES
|
|
|
159,170
|
|
|
|
165,031
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS'
EQUITY (DEFICIT)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred
stock, no par value; 5,000,000 shares
|
|
|
|
|
|
|
|
|
authorized,
-0-
shares issued and outstanding
|
|
|
- |
|
|
|
-
|
|
Common
stock, no par value; 50,000,000 shares
|
|
|
|
|
|
|
|
|
authorized,
48,503,749 and 47,503,749 shares
|
|
|
|
|
|
|
|
|
issued
and outstanding, respectively
|
|
|
18,821,100
|
|
|
|
18,746,100
|
|
Additional
paid-in capital
|
|
|
1,986,398
|
|
|
|
1,986,398
|
|
Treasury
stock
|
|
|
|
(82,357 |
) |
|
|
(82,357 |
) |
Accumulated
other comprehensive income
|
|
|
398,443
|
|
|
|
383,407
|
|
Accumulated
deficit
|
|
|
(21,177,550 |
) |
|
|
(21,033,386 |
) |
|
|
|
|
|
|
|
|
|
|
|
Total
Stockholders' Equity (Deficit)
|
|
|
(53,966 |
) |
|
|
162
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL
LIABILITIES AND STOCKHOLDERS'
|
|
|
|
|
|
|
|
|
EQUITY
(DEFICIT)
|
|
$ |
105,204
|
|
|
$ |
165,193
|
|
The
accompanying condensed notes are an integral part of these interim consolidated
financial statements.
3
|
|
Consolidated
Statements of Operations and Comprehensive Income
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
the Three
|
|
|
|
|
|
Months
Ended
|
|
|
|
|
|
September
30,
|
|
|
|
|
|
2005
|
|
|
2004
|
|
|
|
|
|
|
|
|
|
|
REVENUES
|
|
$ |
-
|
|
|
$ |
5,572
|
|
|
|
|
|
|
|
|
|
|
|
|
COST
OF SALES
|
|
|
-
|
|
|
|
3,902
|
|
|
|
|
|
|
|
|
|
|
|
|
GROSS
PROFIT
|
|
|
-
|
|
|
|
1,670
|
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING
EXPENSES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
and development
|
|
|
11,557
|
|
|
|
185,408
|
|
Depreciation
and amortization
|
|
|
13,324
|
|
|
|
17,072
|
|
General
and administrative
|
|
|
118,021
|
|
|
|
135,789
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Operating Expenses
|
|
|
142,902
|
|
|
|
338,269
|
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING
LOSS
|
|
|
(142,902 |
) |
|
|
(336,599 |
) |
|
|
|
|
|
|
|
|
|
|
|
OTHER
INCOME (EXPENSE)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
income
|
|
|
-
|
|
|
|
1,752
|
|
Interest
expense
|
|
|
(1,816 |
) |
|
|
-
|
|
Other
income (loss)
|
|
|
554
|
|
|
|
(2,107 |
) |
|
|
|
|
|
|
|
|
|
|
|
Total
Other Income (Expense)
|
|
|
(1,262 |
) |
|
|
(355 |
) |
|
|
|
|
|
|
|
|
|
|
|
NET
LOSS
|
|
|
(144,164 |
) |
|
|
(336,954 |
) |
|
|
|
|
|
|
|
|
|
|
|
OTHER
COMPREHENSIVE INCOME
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign
currency translation adjustments
|
|
|
15,036
|
|
|
|
6,848
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Other Comprehensive Income
|
|
|
15,036
|
|
|
|
6,848
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COMPREHENSIVE
LOSS
|
|
$ |
(129,128 |
) |
|
$ |
(330,106 |
) |
|
|
|
|
|
|
|
|
|
|
|
BASIC
AND DILUTED LOSS PER SHARE
|
|
$ |
(0.00 |
) |
|
$ |
(0.01 |
) |
|
|
|
|
|
|
|
|
|
|
|
WEIGHTED
AVERAGE NUMBER
|
|
|
|
|
|
|
|
|
OF
SHARES OUTSTANDING
|
|
|
47,998,254
|
|
|
|
40,836,613
|
|
The
accompanying condensed notes are an integral part of these interim consolidated
financial statements.
4
|
|
Consolidated
Statements of Cash Flows
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
the Three
|
|
|
|
|
|
|
Months
Ended
|
|
|
|
|
|
|
September
30,
|
|
|
|
|
|
|
2005
|
|
|
2004
|
|
CASH
FLOWS FROM OPERATING ACTIVITIES
|
|
|
|
|
|
|
Net
loss
|
|
|
$ |
(144,164 |
) |
|
$ |
(336,954 |
) |
Adjustments
to reconcile net loss to net cash
|
|
|
|
|
|
|
|
|
used
by operating activities:
|
|
|
|
|
|
|
|
|
Depreciation
and amortization
|
|
|
13,324
|
|
|
|
17,072
|
|
Common
stock issued for services
|
|
|
10,837
|
|
|
|
43,500
|
|
Changes
in operating assets and liabilities
|
|
|
|
|
|
|
|
|
Decrease
in accounts receivable
|
|
|
458
|
|
|
|
20,829
|
|
Decrease
(Increase) in inventories
|
|
|
15
|
|
|
|
(15,759 |
) |
Decrease
in prepaid expenses and other assets
|
|
|
48,926
|
|
|
|
1,698
|
|
Increase
(decrease) in accounts payable
|
|
|
|
|
|
|
|
|
and
accrued expenses
|
|
|
18,271
|
|
|
|
(20,106 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Net
Cash Used by Operating Activities |
|
|
(52,333 |
) |
|
|
(289,720 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM INVESTING ACTIVITIES
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM FINANCING ACTIVITIES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sale
of common stock for cash
|
|
|
64,163
|
|
|
|
-
|
|
Payment
of notes payable
|
|
|
(24,132 |
) |
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
Cash Provided by Financing Activities |
|
40,031
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EFFECT
OF EXCHANGE RATE CHANGES
|
|
|
15,036
|
|
|
|
(5,491 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
NET
INCREASE (DECREASE) IN CASH
|
|
|
2,734
|
|
|
|
(295,211 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
CASH
AT BEGINNING OF PERIOD
|
|
|
9,497
|
|
|
|
310,959
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH
AT END OF PERIOD
|
|
$ |
12,231
|
|
|
$ |
15,748
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUPPLIMENTAL
DISCLOSURES OF
|
|
|
|
|
|
|
|
|
CASH
FLOW INFORMATION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH
PAID FOR:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
$ |
1,816
|
|
|
$ |
-
|
|
Income
Taxes
|
|
$ |
-
|
|
|
$ |
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NON
CASH FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
Common
stock issued for debt
|
|
$ |
24,132
|
|
|
$ |
-
|
|
The
accompanying condensed notes are an integral part of these interim consolidated
financial statements.
5
SANGUI
BIOTECH INTERNATIONAL,
INC.
Notes
to
the Consolidated Financial
Statements
NOTE
1 -
BASIS OF PRESENTATION
The
accompanying consolidated financial statements have been prepared without audit
in accordance with accounting principles generally accepted in the United States
of America for interim financial information and with the instructions to Form
10-QSB and Item 301 of Regulation S-B. Certain information and footnote
disclosures normally included in financial statements prepared in accordance
with accounting principles generally accepted in the United States of America
have been condensed or omitted pursuant to such rules and regulations. The
unaudited consolidated financial statements and notes should, therefore, be
read
in conjunction with the consolidated financial statements and notes thereto
in
the Company's Form 10-KSB for the year ended June 30, 2005. In the opinion
of management, all adjustments (consisting of normal and recurring adjustments)
considered necessary for a fair presentation, have been included. The
results of operations for the three-month period ended September 30, 2005 are
not indicative of the results that may be expected for the full fiscal year
ending June 30, 2006.
NOTE
2 -
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature
of Business
Sangui
Biotech International, Inc., incorporated in Colorado in 1995, and its wholly
owned subsidiaries, Sangui Biotech, Inc., SanguiBioTech AG, GlukoMediTech AG,
and Sangui BioTech PTE Ltd. (collectively, the "Company") have been engaged
in
the research, development, manufacture, and sales of medical and cosmetic
products.
On
June 30,
2003, GlukoMediTech AG ("Gluko AG") was merged into Sangui BioTech AG ("Sangui
AG"). Effective November 4, 2003, Sangui AG was converted into Sangui
BioTech GmbH (Sangui GmbH). After completion of the restructuring, Sangui
GmbH, which is headquartered in Witten, Germany, is engaged in the development
of artificial oxygen carriers (external applications of hemoglobin, blood
substitutes and blood additives) as well as in the development of glucose
implant sensors.
The
operations of Sangui BioTech, Inc. and Sangui BioTech PTE Ltd Singapore, two
former wholly-owned subsidiaries, were discontinued and dissolved during
2002.
The
operations of Sangui BioTech, Inc. ("Sangui USA") were discontinued during
2002
upon the sale of its in vitro immunodiagnostics business and the subsequent
merger of Sangui USA with and into the parent company, Sangui BioTech
International, Inc., effective December 31, 2002. Sangui BioTech PTE Ltd
("Sangui Singapore") was a regional office for the Company that carried out
research and development projects in conjunction with Sangui GmbH and Sangui
Singapore. The Company discontinued the operations of Sangui Singapore in
August 2002. The Singapore office was closed effective December 31,
2002.
Consolidation
The
consolidated financial statements include the accounts of Sangui BioTech
International, Inc. and its wholly owned subsidiaries. All significant
intercompany accounts and transactions have been eliminated in
consolidation. Certain amounts in the three months ended September 30,
2004 have been reclassified to conform to the three months ended September
30,
2005 presentation. These reclassifications have no effect on previously
reported net loss.
6
SANGUI
BIOTECH INTERNATIONAL,
INC.
Notes
to
the Consolidated Financial
Statements
NOTE
2 -
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Foreign
Currency Translation
Assets
and
liabilities of the Company's foreign operations are translated into U.S. dollars
at period-end exchange rates. Net exchange gains or losses resulting from
such translation are excluded from net loss but are included in comprehensive
income (loss) and accumulated in a separate component of stockholders'
equity. Income and expenses are translated at weighted average exchange
rates for the period.
Risk
and Uncertainties
The
Company's
line of future pharmaceutical products (artificial oxygen carriers or blood
substitute and additives) and in-vivo biosensors (glucose implant sensor) being
developed by Sangui GmbH, are deemed as medical devices or biologics, and as
such are governed by the Federal Food and Drug and Cosmetics Act and by the
regulations of state agencies and various foreign government agencies. The
pharmaceutical and biosensor products, under development in Germany, will be
subject to more stringent regulatory requirements, because they are in vivo
products for humans. The Company and its subsidiaries have no experience
in obtaining regulatory clearance on these types of products. Therefore,
the Company will be subject to the risks of delays in obtaining or failing
to
obtain regulatory clearance.
The
accompanying consolidated financial statements have been prepared assuming
the
Company will continue as a going concern, which contemplates, among other
things, the realization of assets and satisfaction of liabilities in the normal
course of business. The Company has accumulated deficit of $21,177,550 as
of September 30, 2005 and has been significantly reducing its working capital
since June 30, 2004. The Company incurred a net loss applicable to common
stockholders of $144,164 and used cash in operating activities of $52,333 for
the three months ended September 30, 2005. These conditions raise
substantial doubt about the Company's ability to continue as a going
concern. The Company expects to continue to incur significant capital
expenses in pursuing its business plan to market its products and expand its
product line, while obtaining additional financing through stock offerings
or
other feasible financing alternatives. In order for the Company to continue
its
operations at its existing levels, the Company will require significant
additional funds over the next twelve months. Therefore, the Company is
dependent on funds raised through equity or debt offerings. Additional
financing may not be available on terms favorable to the Company, or at all.
If
these funds are not available the Company may not be able to execute its
business plan or take advantage of business opportunities. The ability of
the Company to obtain such additional financing and to achieve its operating
goals is uncertain. In the event that the Company does not obtain additional
capital or is not able to increase cash flow through the increase of sales,
there is a substantial doubt of its being able to continue as a going concern.
The accompanying condensed consolidated financial statements do not
include any adjustments that might result from the outcome of this
uncertainty.
Cash
and Cash Equivalents
The
Company
maintains its cash in bank accounts in Germany. Cash and cash equivalents
include time deposits for which the Company has no requirements for compensating
balances. The Company has not experienced any losses in its uninsured bank
accounts. At September 30, 2005 the Company had no cash
equivalents.
7
SANGUI
BIOTECH INTERNATIONAL,
INC.
Notes
to
the Consolidated Financial
Statements
NOTE
2 -
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Revenue
Recognition
Revenue
is
recognized when the sales amount is determined, shipment of goods to the
customer has occurred and collection is reasonably assured. Product is
shipped FOB origination.
Research
and Development
Research
and
development costs are charged to operations as they are
incurred. Legal fees and other direct costs incurred in obtaining and
protecting patents are expensed as incurred.
Basic
and Diluted Earnings (Loss) Per Common Share
Basic
earnings (loss) per common share is computed by dividing income (loss) available
to common stockholders by the weighted average number of common shares
outstanding during the period of computation. Diluted earnings (loss) per
share gives effect to all potential dilutive common shares outstanding during
the period of compensation. The computation of diluted earnings (loss) per
share does not assume conversion, exercise or contingent exercise of securities
that would have an antidilutive effect on earnings. As of September 30,
2005 and 2004, the Company had no potentially dilutive securities that would
affect the loss per share if they were to be dilutive.
Comprehensive
Income (Loss)
Total
comprehensive income (loss) represents the net change in stockholders' equity
during a period from sources other than transactions with stockholders and
as
such, includes net earnings (loss). For the Company, the component of
other comprehensive income (loss) is the change in the cumulative foreign
currency translation adjustments and is recorded as a component of stockholders'
equity (deficit).
New
Accounting Pronouncements
In
December
2004, the FASB issued SFAS No. 123R "Share Based Payment." This statement
is a revision of SFAS Statement No. 123, "Accounting for Stock-Based
Compensation" and supersedes APB Opinion No. 25, "Accounting for Stock Issued
to
Employees," and its related implementation guidance. SFAS 123R addresses
all forms of share based payment ("SBP") awards, including shares issued under
employee stock purchase plans, stock options, restricted stock and stock
appreciation rights. Under SFAS 123R, SBP awards result in a cost that
will be measured at fair value on the awards' grant date, based on the estimated
number of awards that are expected to vest and will be reflected as compensation
cost in the historical financial statements. This statement is effective
for public entities as of the beginning of the first interim or annual reporting
period that begins after June 15, 2005.
In
May 2005,
the FASB issued Statement of Financial Accounting Standards No.
154“Accounting Changes and Error Corrections, an amendment of APB Opinion
20
and FASB Statement No. 3,” which changes the requirements for accounting
for and reporting on a change in accounting principle. This statement is
effective for accounting changes and corrections of errors made in fiscal years
beginning after December 15, 2005. We believe that the adoption of SFAS
No. 154 will not have a material impact on our results of
operations.
8
SANGUI
BIOTECH INTERNATIONAL,
INC.
Notes
to
the Consolidated Financial
Statements
NOTE
2 -
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
New
Accounting Pronouncements (Continued)
In
June 2006,
the FASB issued Financial Interpretation No. (FIN) 48, “Accounting for
Uncertainty in Income Taxes - an interpretation of FASB Statement 109.”
FIN 48 prescribes a recognition threshold and a measurement attribute
for
the financial statement recognition and measurement of a tax position taken
or
expected to be taken in a tax return. This interpretation also provides
guidance on de-recognition, classification, interest and penalties, accounting
in interim periods, disclosure and transition. This interpretation is
effective for fiscal years beginning after December 15, 2006. The Company
is currently evaluating the impact of applying the various provisions of FIN
48.
In
September
2006, the FASB issued SFAS No. 157, “Fair Value Measurements,” that
provides guidance for using fair value to measure assets and liabilities.
Under SFAS 157, fair value refers to the price that would be received to sell
an
asset or paid to transfer a liability in an orderly transaction between market
participants in the market in which the reporting entity transacts. SFAS
157 establishes a fair value hierarchy that prioritizes the information used
to
develop the assumptions that market participants would use when pricing the
asset or liability. The fair value hierarchy gives the highest priority to
quoted prices in active markets and the lowest priority to unobservable data.
In addition, SFAS 157 requires that fair value measurements be separately
disclosed by level within the fair value hierarchy. This standard will be
effective for financial statements issued for fiscal periods beginning after
November 15, 2007 and interim periods within those fiscal years. SFAS 157
had no effect on the Company’s financial statements for the period ended
September 30, 2005.
NOTE
3 -
STOCKHOLDERS' EQUITY
During
the
three months ended September 30, 2006, the Company issued 1,000,000 shares
of
common stock to an unrelated individual for $40,031 in cash, $10,837 in
services, and $24,132 in payment of debts.
NOTE
4 -
COMMITMENTS AND CONTINGENCIES
Litigation
The
Company
may, from time to time, be involved in various legal disputes resulting from
the
ordinary course of operating its business. Management is currently not able
to
predict the outcome of any such cases. However, management believes that
the amount of ultimate liability, if any, with respect to such actions will
not
have a material effect on the Company's financial position or results of
operations.
On
June 15,
2005, SanguiBioTech GmbH was served with a lawsuit, Amtsgericht Witten, Case
No.
2 C 429/05. The plaintiff is a supplier of packaging foils for
certain medical products. He claims payment of invoices amounting to
approximately $ 8,500. The Company had rejected the delivery of the
goods covered by the invoices due to poor quality. The claim was
settled by order of the Court on September 7, 2005, whereby Sangui agreed to
pay
an amount of approximately $6,406, including court fees.
9
SANGUI
BIOTECH INTERNATIONAL,
INC.
Notes
to
the Consolidated Financial
Statements
NOTE
4 -
COMMITMENTS AND CONTINGENCIES (Continued)
Indemnities
and Guarantees
During
the
normal course of business, the Company has made certain indemnities and
guarantees under which it may be required to make payments in relation to
certain transactions. These indemnities include certain agreements with
the Company's officers, under which the Company may be required to indemnify
such person for liabilities arising out of their employment relationship.
The duration of these indemnities and guarantees varies and, in certain
cases, is indefinite. The majority of these indemnities and guarantees do
not provide for any limitation of the maximum potential future payments the
Company could be obligated to make. Historically, the Company has not been
obligated to make significant payments for these obligations and no liabilities
have been recorded for these indemnities and guarantees in the accompanying
consolidated balance sheet.
NOTE
5 –
SUBSEQUENT EVENTS
Issuance
of Common Stock
In
January
2006, the Company sold 1,495,960 shares of its common stock to a European
investor yielding a cash inflow of $135,758.
Loan
Agreement with FID Esprit AG
On
April 4,
2006, the Company entered into a loan agreement with FID Esprit AG.
Pursuant to the terms of the loan agreement, FID Esprit AG loaned the Company
approximately $48,264 with interest of six percent per annum. The Company
has the option of paying the loan and interest in cash or with shares of
SanguiBioTech AG common stock, its wholly-owned subsidiary, valued at 50% of
the
average Hamburg OTC trading price over the four weeks prior to
repayment.
Loan
Agreement with Feedback AG
On
June 9,
2006, the Company entered into a loan agreement with Feedback
AG. Pursuant to the terms of the loan agreement, Feedback AG loaned
the Company approximately $96,527 with interest of six percent per
annum. The Company has the option of paying the loan and interest in cash
or with shares of SanguiBioTech AG common stock, its wholly-owned subsidiary,
valued at 50% of the average Hamburg OTC trading price over the four weeks
prior
to repayment.
Second
Loan Agreement with Feedback AG
On
July 21,
2006, the Company entered into a second loan agreement with Feedback AG.
Pursuant to the terms of the loan agreement, Feedback AG loaned the Company
approximately $18,100 for the purpose of preparing a shareholders meeting.
The interest on this loan is set at six percent per annum. The Company is
to pay the loan and interest off utilizing its common stock following the
shareholders meeting, however, if a shareholders meeting has not been held
as of
July 30, 2007, then the loan and interest are due and payable in
cash.
10
SANGUI
BIOTECH INTERNATIONAL,
INC.
Notes
to
the Consolidated Financial
Statements
NOTE
5 –
SUBSEQUENT EVENTS (Continued)
Agreement
with ERC Nano Med S.A. de C.V.
On
October
13, 2006, the Company entered into a Distribution, Collaboration, and
Commercialization Agreement through its wholly owned subsidiary with ERC S.A.
de
C.V., a division of ERC Nano Med. of Mexico (“ERC”). Under the terms
of the agreement the Company is granting the exclusive distribution rights
of
its i) hemospray, ii) wound cleaner liquid gel, iii) chitoskin wound pads,
and
iv) bloodadditiv to ERC. In return, ERC is to work with the various
Mexican Health Authorities necessary to grant government approvals necessary
for
the products to be sold and distributed in Mexico. All costs for
obtaining the necessary approvals in Mexico are to be born by ERC.
Additional
Loans
From
January
2006 to April 2007 the Company borrowed money from four separate European
companies and their affiliates to supplement its ongoing operational cash
flow. The Company issued notes in exchange for cash pursuant to the
following terms: All notes are due and payable in the fifth
anniversary of issuance at a rate of 5% simple interest. The Company,
in its sole discretion, has the right to convert these notes, including all
unpaid principal and any interest thereon, into shares of the Company’s common
stock at the rate of approximately $0.11 per share at any time prior to full
repayment or on the Due Date. The total amount borrowed under these notes
was $512,959.
Letter
of Intent with Tycoon Venture Capital
As
of April
9, 2007, the Company entered into a letter of intent with Tycoon Venture Capital
& Investment Ltd., London, UK, according to which Tycoon intends to acquire
a stake of 25% in the Company. As part of the planned agreement Tycoon
Venture Capital & Investment plans to offer the Company a mezzanine loan of
up to approximately $ 9.15 million.
Letter
of Intent with Tycoon Consulting
As
of February 6, 2007, the Company and Tycoon Consulting (UK), Bristol, UK,
entered into an agreement, according to which Tycoon agreed to undertake the
marketing of Sangui cosmetics in several Arab countries, including Saudi Arabia,
the United Arabian Emirates, Kuwait, Bahrain, Jordan and Egypt. Tycoon was granted
exclusive
distribution rights for the Company’s cosmetics for the region. As of May
23, 2007, Tycoon disclosed that it had signed contracts with Arab companies
to
further promote this venture.
11
ITEM
2 -
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
Forward-looking
Statements
The
following
discussion of our financial condition and results of operations should be read
in conjunction with the consolidated financial statements and the related notes
thereto included elsewhere in this quarterly report. Some of the information
in
this quarterly report contains forward-looking statements, including statements
related to anticipated operating results, margins, growth, financial resources,
capital requirements, adequacy of the Company's financial resources, trends
in
spending on research and development, the development of new markets, the
development, regulatory approval, manufacture, distribution, and commercial
acceptance of new products, and future product development efforts. Investors
are cautioned that forward-looking statements involve risks and uncertainties,
which may affect our business and prospects, including but not limited to,
the
Company's expected need for additional funding and the uncertainty of receiving
the additional funding, changes in economic and market conditions, acceptance
of
our products by the health care and reimbursement communities, new development
of competitive products and treatments, administrative and regulatory approval
and related considerations, health care legislation and regulation, and other
factors discussed in our filings with the Securities and Exchange
Commission.
GENERAL
The
Company's
mission is the development of novel and proprietary pharmaceutical, medical
and
cosmetic products. The Company develops its products through its
wholly owned German subsidiary Sangui GmbH. The Company is seeking to
market and sell some or all of their products through partnerships with industry
partners.
The
focus of
Sangui GmbH has been the development of oxygen carriers capable of providing
oxygen transport in humans in the event of acute and/or chronic lack of oxygen
dueto arterial occlusion, anaemia or blood loss whether due to surgery, trauma,
or other causes. Sangui GmbH has thus far focused its development and
commercialization efforts of such artificial oxygen carriers by reproducing
and
synthesizing polymers out of native hemoglobin of defined molecular
sizes. Sangui GmbH, has in addition developed external applications
of oxygen transporters in the medical and cosmetic fields in the form of gels
and emulsions for the regeneration of the skin
Sangui
GmbH
holds the exclusive distribution rights for Chitoskin wound pads for the
European Union and various other countries. Sangui GmbH has filed a
patent cooperation treatment applications (“PCT”) for the production and use of
improved Chitoskin wound pads using gelatine instead of collagen as the carrier
substance.
ARTIFICIAL
OXYGEN CARRIERS
Sangui
GmbH
develops several products based on polymers of purified natural porcine
hemoglobin with oxygen carrying abilities that are similar to native
hemoglobin. These are (1) oxygen carrying blood additives and (2)
oxygen carrying blood volume substitutes.
In
December
1997, Sangui GmbH decided that porcine hemoglobin should be used as the basic
material for its artificial oxygen carriers. In March 1999, Sangui
GmbH decided which hemoglobin hyperpolymer would go into preclinical
investigation and that glutaraldehyde would be utilized as a cross linker,
and
further that the polymer hemoglobin be chemically masked to prevent protein
interaction in blood plasma. The fine adjustment of the molecular
formula of the artificial oxygen carriers - optimized for laboratory scale
production - was finalized in the summer of 2000.
The
experiments completed in Sangui GmbH’s laboratories demonstrated that it is
possible to polymerize hemoglobins isolated from porcine blood resulting in
huge
soluble molecules, so-called hyperpolymers. In August 2000, Sangui
GmbH finalized its work on the pharmaceutical formulation of the oxygen carrier
for laboratory scale. In February 2001 a pilot production in a
laboratory scale was carried out in SGBI's clean room. The resulting
product was applied in single volunteers in pilot self-experiments.
The
blood
additives and blood substitute projects were halted in 2003 due to the lack
of
financing for the pre-clinical test phase of the blood additives. In
October, 2006, subsequent to the period covered by this report, a contract
was
entered into between Sangui GmbH and ERC Nano Med S.A. de C.V. of Monterrey,
Mexico (“ERC”), which provides that ERC will establish a production facility in
Mexico to produce sufficient quantities of the blood additive. In
cooperation with the medical faculty of Monterrey University and the Mexican
National Health Organizations, ERC will initiate all necessary steps to begin
the pre-clinical test phase for the products as soon as possible. It
is anticipated that this will lead to the FDA authorization process in due
course. The authorization process will be managed in cooperation with
Medicoforum group of Hannover, Germany, a company specializing in international
pharmaceutical and medical product authorizations,
According
to
regulatory requirements, all drugs must complete preclinical and clinical trials
before approval (e.g. Federal Drug Administration approval, see Certain Business
Risks below) and market launch. The Company’s management believes
that the European and FDA approval process will take at a minimum several years
to complete.
NANO
FORMULATIONS FOR THE REGENERATION OF THE SKIN
Healthy
skin
is supplied with oxygen both from the inside as well as through diffusion from
the outside. A lack of oxygen will cause degenerative alterations,
ranging from premature aging, to surface damage, and even as extensive as
causing open wounds. The cause for the lack of oxygen may be a part
of the normal aging process, but it may also be caused by burns, radiation,
trauma, or a medical condition. Impairment of the blood flow, for
example caused by diabetes mellitus or by chronic venous insufficiency, can
also
lead to insufficient oxygen supply and the resulting skin damage.
The
nano-emulsion-based preparations now being sold by Sangui GmbH have been
designed to supporting the regeneration of the skin by improving its oxygen
supply. The products Sangui GmbH are currently focussing on are an
anti-aging formulation and treatment and an anti-cellulite formulation for
the
cosmetics market. The products were thoroughly tested by an
independent research institute and received top marks for skin moisturization,
and enhanced skin elasticity, respectively.
Sangui’s
cosmetic business model is reliant upon cooperation with its manufacturing
and
distribution partners. Sangui has its various formulations produced
by a contract manufacturer and sells quantities of the products either in bulk
or in customized private label packaging, as requested. In addition,
Sangui started to sell its cosmetic products under its own brand “Pure
MO2isture” via an internet shop as of mid September, 2006.
Sales
of the
anti-cellulite products started subsequent to this report in August, 2005 via
two German TV shop programs. Sales figures in this distribution
channel are stable, according to information provided by our distribution
partner. Additionally, distribution partners in Argentina and Mexico
have purchased launch quantities in November, 2005, and July, 2006,
respectively.
CHITOSKIN
WOUND PADS
In
March,
2005, SanguiBioTech GmbH was awarded the CE mark for this
product. The CE mark authorizes the company to distribute and sell
this medical product in the member countries of the European
Union. At the same time Sangui GmbH successfully passed the ISO
9001:2000 (General Quality Management System) and ISO 13485:2003 (Quality
Management System Medical Products) audits, and obtained the respective
certifications. The “Chitoskin” trademark was already granted to the
company for the European countries effective November 1, 2004.
Karl
Beese
GmbH, a leading German vendor and distributor of hospital supplies began
marketing and distributing the wound pad product in August, 2005, and has placed
several subsequent orders with the company. In addition, Karl Beese
will deliver large quantities of the wound pad product to a Czech distribution
partner through summer 2006.
FINANCIAL
POSITION
The
Company's
current assets decreased $1,693, or 4%, from June 30, 2005 to $36,588 at
September 30, 2005. The decrease is primarily attributable to a decrease in
prepaid expenses and other assets of $3,954. This decrease was partially offset
by a $2,734 increase in cash during the period.
The
Company's
net property and equipment decreased $10,834, or 32% from June 30, 2005 to
$22,774 at September 30, 2005. The decrease is primarily attributable to current
period depreciation.
The
Company
funded its operations primarily through its existing cash reserves and cash
received from the sale of common stock. The Company's stockholders' equity
decreased $54,128. The primary decrease is caused by the Company's current
period net loss of $144,164.
RESULTS
OF OPERATIONS
Three
months ended September 30, 2005 and 2004:
RESEARCH
AND
DEVELOPMENT. Research and development expenses decreased significantly
to $11,557 in 2005 from $185,408 in 2004. The decrease is mainly attributed
to
the Company lacking the requisite funding and a reduction in
staff. The Company is seeking additional sources to provide financing
for additional research and development.
GENERAL
AND
ADMINISTRATIVE. General and administrative expenses decreased 13% to $118,021
in
2005 from $135,789 in 2004. This decrease is mainly attributed to the ongoing
refocusing program and a reduction in staff.
DEPRECIATION
AND AMORTIZATION. Depreciation decreased 12% to $13,324 in 2005 from $17,072
in
2004. This decrease is mainly attributed to the ongoing restructuring of Sangui
GmbH.
NET
LOSS. As
a result of the above factors, the Company's consolidated net loss was $144,164,
or $0.00 per common share, for the three months ended September 30, 2005,
compared to $336,954, or $0.01 per common share, during the comparable period
in
2004.
LIQUIDITY
AND CAPITAL RESOURCES
For
the three
months ended September 30, 2005, net cash used in operating activities decreased
to $52,333 from $289,720 in the corresponding period in 2004, primarily related
to a decrease in the Company's consolidated net loss as a result of the ongoing
refocusing program.
The
Company
had a working capital deficit of $122,582 at September 30, 2005, a decrease
of
$4,168 from June 30, 2005. At September 30, 2005, the Company had
cash of $12,231. The Company will need substantial additional funding to fulfill
its business plan and the Company intends to explore financing sources for
its
future development activities. No assurance can be given that these efforts
will
be successful.
ITEM
3
- CONTROLS AND PROCEDURES
(a)
Evaluation of disclosure controls and procedures. Our principal executive
officer and principal financial officer have evaluated the effectiveness of
our
disclosure controls and procedures (as defined in Rules 13a-14(c) and 15d-14(c)
under the Exchange Act), as of a date within 90 days of the filing date of
this
Quarterly Report on Form 10-QSB. Based on such evaluation, they have concluded
that as of such date, our disclosure controls and procedures are have not been
effective or designed to ensure that information required to be disclosed by
us
in reports that we file or submit under the Exchange Act is recorded, processed,
summarized and reported within the time periods specified in applicable SEC
rules and forms. Our principal executive officer and principal
financial officer are currently working to streamline our disclosure controls
and procedures, so as to adequately comply with such SEC rules and
forms.
(b)
Changes
in internal controls. There were no significant changes in our internal controls
or in other factors that could significantly affect these controls subsequent
to
the date of evaluation by our principal executive officer and principal
financial officer.
PART
II -
OTHER INFORMATION
ITEM
1
- LEGAL PROCEEDINGS
Subsequent
to
the period covered by this report, on June 15, 2005, SanguiBioTech GmbH was
served with a lawsuit, Amtsgericht Witten, Case No. 2 C 429/05. The
plaintiff is a supplier of packaging foils for certain medical
products. He claims payment of invoices amounting to approximately $
8,500. The Company had rejected the delivery of the goods covered by
the invoices due to poor quality. The claim was settled by order of
the Court on September 7, 2005, whereby Sangui agreed to pay an amount of
approximately $6,406., including court fees.
The
Company
is not aware of pending claims or assessments which may have a material adverse
impact on the Company’s financial position or results of
operations.
ITEM
2
- UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
During
the
three months ended September 30 2005, the Company issued 1,000,000 shares of
common stock for cash of $40,031, payment of debt of $24,132 and services of
$10,837.
Subsequent
to
September 30, 2005 the Company issued 1,495,960 shares of common stock for
a
cash inflow of $135,758.
ITEM
3
- DEFAULTS UPON SENIOR SECURITIES
None.
ITEM
4
- SUBMISSION OF MATTERS TO A VOTE OF SECURITIES HOLDERS
None.
ITEM
5
- OTHER INFORMATION
Sangui
Directors Christpoh Ludz and Markus Volpers resigned effective February 7,
2005.
The Board appointed Thomas Striepe, the Vice President of Accounting and
Controlling of Dr. Ludz, GmbH, Hamburg, as a director. The Board of Directors
now consists of Wolfgang Barnikol, Joachim Lutz, Thomas Striepe and Joachim
Fleing.
ITEM
6
- EXHIBITS
31.1
Certification Pursuant to Rule 13a-14(a) and 15d-14(a), filed
herewith.
32.1 Certification
Pursuant to Section 1350 of Title 18 of the United States Code, filed
herewith.
SIGNATURES
Pursuant
to
the requirements of the Securities Exchange Act of 1934, the Registrant has
duly
caused this report to be signed on its behalf by the undersigned thereunto
duly
authorized.
SANGUI
BIOTECH INTERNATIONAL, INC.
Date:
September 13,
2007 /s/ Wolfgang
Barnikol
By:
Wolfgang Barnikol
Chief
Executive Officer and Chief Financial Officer
14